EXAS Exact Sciences Corp

Price (delayed)

$45.3

Market cap

$7.97B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.33

Enterprise value

$10.16B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
EXAS's revenue is up by 20% year-on-year and by 4.8% since the previous quarter
EXAS's gross profit is up by 18% year-on-year and by 4.6% since the previous quarter
Exact Sciences's EPS has decreased by 24% from the previous quarter but it has increased by 8% YoY
The company's net income fell by 25% QoQ and by 3.5% YoY
The company's quick ratio fell by 18% YoY and by 12% QoQ

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
175.95M
Market cap
$7.97B
Enterprise value
$10.16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.42
Price to sales (P/S)
4.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.49
Earnings
Revenue
$1.85B
EBIT
-$733.02M
EBITDA
-$521.28M
Free cash flow
-$355.23M
Per share
EPS
-$4.33
Free cash flow per share
-$2.04
Book value per share
$18.71
Revenue per share
$10.62
TBVPS
$11.96
Balance sheet
Total assets
$6.49B
Total liabilities
$3.23B
Debt
$2.38B
Equity
$3.26B
Working capital
$734.19M
Liquidity
Debt to equity
0.73
Current ratio
2.53
Quick ratio
2.13
Net debt/EBITDA
-4.21
Margins
EBITDA margin
-28.2%
Gross margin
73.9%
Net margin
-40.3%
Operating margin
-39.5%
Efficiency
Return on assets
-11.2%
Return on equity
-21.8%
Return on invested capital
-19.4%
Return on capital employed
-12.2%
Return on sales
-39.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
4.64%
1 week
15%
1 month
-5.82%
1 year
-61.53%
YTD
-41.8%
QTD
15%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$1.85B
Gross profit
$1.37B
Operating income
-$732.12M
Net income
-$745.4M
Gross margin
73.9%
Net margin
-40.3%
The operating margin has increased by 38% year-on-year and by 18% since the previous quarter
The operating income has increased by 26% year-on-year and by 14% since the previous quarter
The company's net income fell by 25% QoQ and by 3.5% YoY
EXAS's revenue is up by 20% year-on-year and by 4.8% since the previous quarter

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
2.42
P/S
4.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.49
Exact Sciences's EPS has decreased by 24% from the previous quarter but it has increased by 8% YoY
The stock's price to book (P/B) is 74% less than its 5-year quarterly average of 8.8 and 50% less than its last 4 quarters average of 4.6
The company's equity fell by 11% YoY and by 3.8% QoQ
EXAS's price to sales (P/S) is 74% less than its 5-year quarterly average of 15.6 and 55% less than its last 4 quarters average of 9.0
EXAS's revenue is up by 20% year-on-year and by 4.8% since the previous quarter

Efficiency

How efficient is Exact Sciences business performance
The company's return on invested capital rose by 39% YoY and by 15% QoQ
Exact Sciences's ROS has increased by 35% YoY and by 15% from the previous quarter
The ROE has contracted by 28% from the previous quarter but it has grown by 19% YoY
EXAS's return on assets is down by 26% since the previous quarter but it is up by 21% year-on-year

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 101% more than the total liabilities
The company's quick ratio fell by 18% YoY and by 12% QoQ
EXAS's current ratio is down by 10% YoY and by 8% QoQ
The company's debt is 27% lower than its equity
EXAS's debt to equity is up by 12% year-on-year and by 4.3% since the previous quarter
The company's equity fell by 11% YoY and by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.